MA43195A1 - Vaccins vectorises a adenovirus recombinants contre le virus de la fievre aphteuse (fmdv) et utilisations correspondantes - Google Patents

Vaccins vectorises a adenovirus recombinants contre le virus de la fievre aphteuse (fmdv) et utilisations correspondantes

Info

Publication number
MA43195A1
MA43195A1 MA43195A MA43195A MA43195A1 MA 43195 A1 MA43195 A1 MA 43195A1 MA 43195 A MA43195 A MA 43195A MA 43195 A MA43195 A MA 43195A MA 43195 A1 MA43195 A1 MA 43195A1
Authority
MA
Morocco
Prior art keywords
fmdv
vaccines against
disease virus
recombinant adenovirus
mouth disease
Prior art date
Application number
MA43195A
Other languages
English (en)
Other versions
MA43195B1 (fr
Inventor
Justin Widener
Leszlie Woodyward
Leonardo Siger
Damodar Ettyreddy
Jason Gall
Duncan McVEY
Tom Burrage
Douglas Brough
Original Assignee
Merial Inc
Genvec Inc
The Government Of The United States Of America As Represented By The Secretary Of Homeland Security
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc, Genvec Inc, The Government Of The United States Of America As Represented By The Secretary Of Homeland Security filed Critical Merial Inc
Publication of MA43195A1 publication Critical patent/MA43195A1/fr
Publication of MA43195B1 publication Critical patent/MA43195B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions ou des vaccins contre le fmdv. L'invention concerne des vecteurs recombinants codant et exprimant des antigènes, des épitopes ou des immunogènes du fmvd qui peuvent être utilisés pour protéger des animaux, en particulier des ovins, des bovins, des caprins ou des porcs, contre le fmvd.
MA43195A 2016-01-29 2017-01-30 Vaccins vectorises a adenovirus recombinants contre le virus de la fievre aphteuse (fmdv) et utilisations correspondantes MA43195B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288540P 2016-01-29 2016-01-29
PCT/US2017/015622 WO2017132666A1 (fr) 2016-01-29 2017-01-30 Vaccins vectorisés à adénovirus recombinants contre le virus de la fièvre aphteuse (fmdv) et utilisations correspondantes

Publications (2)

Publication Number Publication Date
MA43195A1 true MA43195A1 (fr) 2019-04-30
MA43195B1 MA43195B1 (fr) 2020-11-30

Family

ID=58191570

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43195A MA43195B1 (fr) 2016-01-29 2017-01-30 Vaccins vectorises a adenovirus recombinants contre le virus de la fievre aphteuse (fmdv) et utilisations correspondantes

Country Status (22)

Country Link
US (2) US10188721B2 (fr)
EP (1) EP3408398B1 (fr)
JP (1) JP6878464B2 (fr)
KR (1) KR102283303B1 (fr)
CN (1) CN108779474B (fr)
AR (1) AR110458A1 (fr)
AU (1) AU2017212813B2 (fr)
BR (1) BR112018015345A8 (fr)
CA (1) CA3012802A1 (fr)
CY (1) CY1124218T1 (fr)
DK (1) DK3408398T3 (fr)
ES (1) ES2787902T3 (fr)
JO (1) JOP20170022B1 (fr)
MA (1) MA43195B1 (fr)
MX (1) MX2018009244A (fr)
NZ (1) NZ744786A (fr)
PT (1) PT3408398T (fr)
RU (1) RU2725495C9 (fr)
TW (1) TWI760322B (fr)
UY (1) UY37100A (fr)
WO (1) WO2017132666A1 (fr)
ZA (1) ZA201804965B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI760322B (zh) * 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN108997493B (zh) * 2018-08-15 2019-07-09 中国农业科学院兰州兽医研究所 一种全牛源o型口蹄疫病毒广谱中和抗体的制备方法
US11582956B2 (en) * 2018-09-27 2023-02-21 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant adenovirus-based interferon biotherapeutics in swine
CN113817068B (zh) * 2020-12-24 2024-01-30 北京微佰生物科技有限公司 一种以人复制缺陷型重组腺病毒为载体的o型口蹄疫疫苗
CN114957480B (zh) * 2021-02-23 2024-01-30 北京微佰生物科技有限公司 一种以人复制缺陷型重组腺病毒为载体的a型口蹄疫疫苗
CN112852760A (zh) * 2021-03-04 2021-05-28 温氏食品集团股份有限公司 重组鸭肠炎病毒及其应用
US20230149528A1 (en) * 2021-08-18 2023-05-18 The United States Of America, As Represented By The Secretary Of Agriculture Development of mosaic vaccines against foot and mouth disease virus serotype o
WO2023090771A1 (fr) * 2021-11-17 2023-05-25 대한민국(농림축산식품부 농림축산검역본부장) Virus recombiné de la fièvre aphteuse de type o pour induire une réponse immunitaire adaptative robuste et surmonter l'interférence des anticorps d'origine maternelle, et composition vaccinale contre la fièvre aphteuse le contenant
KR20240098952A (ko) 2022-12-21 2024-06-28 대한민국(농림축산식품부 농림축산검역본부장) 구제역백신의 무침 피내 접종방법
KR20240098948A (ko) 2022-12-21 2024-06-28 대한민국(농림축산식품부 농림축산검역본부장) 장기 면역 유도가 가능한 피내접종용 구제역 백신 조성물
KR20240098951A (ko) 2022-12-21 2024-06-28 대한민국(농림축산식품부 농림축산검역본부장) 초기 방어가 가능한 피내접종용 구제역 백신 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
EP0138854B1 (fr) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Sequences d'acides amines antigeniquement actives
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
DE3730599A1 (de) 1986-09-12 1988-07-07 Genentech Inc Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
ZA915593B (en) 1990-07-24 1993-03-31 Novagene Inc Herpesvirus-based viral vector which expresses a foot and mounth disease virus epitope on the surface of virus-infected cells and on the surface of virus particles,and vaccine against foot and mounth disease containing the same
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
EP0826063A1 (fr) 1995-04-25 1998-03-04 Vical Incorporated Formulations en ampoule unidose de complexes adn/lipides
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
EP0930893B1 (fr) 1996-10-11 2005-04-13 The Regents of The University of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2810888B1 (fr) 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
RU2294211C2 (ru) * 2001-01-19 2007-02-27 Цитос Байотекнолоджи Аг Композиция и способ для иммунизации, способ продуцирования неприродного, упорядоченного и повторяющегося массива антигенов
SI1651265T1 (sl) 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
CA2571560C (fr) * 2004-06-25 2016-04-12 Merial Limited Genes du virus de la fievre aphteuse exprimant des recombines avipox
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
RU2555342C2 (ru) 2009-09-10 2015-07-10 Мериал Лимитед Новые вакцинные составы, включающие сапонинсодержащие адъюванты
AU2011224188B2 (en) * 2010-03-12 2015-01-22 Boehringer Ingelheim Animal Health USA Inc. Bluetongue virus recombinant vaccines and uses thereof
US8765141B2 (en) * 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
US10010605B2 (en) 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof
TWI760322B (zh) * 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途

Also Published As

Publication number Publication date
DK3408398T3 (da) 2020-02-10
KR20180121896A (ko) 2018-11-09
ZA201804965B (en) 2019-07-31
AU2017212813A1 (en) 2018-08-16
TW201735944A (zh) 2017-10-16
US10493144B2 (en) 2019-12-03
PT3408398T (pt) 2020-02-25
CN108779474B (zh) 2022-10-18
US20190134183A1 (en) 2019-05-09
AR110458A1 (es) 2019-04-03
EP3408398A1 (fr) 2018-12-05
KR102283303B1 (ko) 2021-07-28
MA43195B1 (fr) 2020-11-30
JOP20170022B1 (ar) 2021-08-17
ES2787902T3 (es) 2020-10-19
TWI760322B (zh) 2022-04-11
MX2018009244A (es) 2019-07-10
NZ744786A (en) 2020-05-29
BR112018015345A2 (pt) 2018-12-18
AU2017212813B2 (en) 2020-10-08
UY37100A (es) 2017-08-31
CA3012802A1 (fr) 2017-08-03
EP3408398B1 (fr) 2019-11-27
CY1124218T1 (el) 2022-11-25
RU2018130813A (ru) 2020-03-03
BR112018015345A8 (pt) 2022-06-28
RU2725495C2 (ru) 2020-07-02
US10188721B2 (en) 2019-01-29
WO2017132666A1 (fr) 2017-08-03
US20170216422A1 (en) 2017-08-03
JP6878464B2 (ja) 2021-05-26
RU2725495C9 (ru) 2020-09-01
JP2019507184A (ja) 2019-03-14
RU2018130813A3 (fr) 2020-03-03
CN108779474A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
MA43195A1 (fr) Vaccins vectorises a adenovirus recombinants contre le virus de la fievre aphteuse (fmdv) et utilisations correspondantes
MA40151A1 (fr) Vaccins de recombinaison fmdv et leurs utilisations
MA34087B1 (fr) Vaccins recombinants contre le virus de la langue bleue et leurs utilisations
MX2024001190A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MA42640A1 (fr) Protéines de fusion de dmdv et e2 et leurs utilisations
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MA40902A (fr) Vaccins hpv16 thérapeutiques
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
WO2007024947A3 (fr) Vaccins contre la grippe canine
MX2017003121A (es) Formulaciones de anticuerpos.
BR112017027895A2 (pt) vetores virais recombinantes contendo proteínas menores de prrsv e métodos de fabricação e utilização destes
PH12017500216A1 (en) Vaccine in serotype-9 fowl adenovirus recombinant vector
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2011004219A (es) Vacuna contra el virus de la peste equina africana.
MA44513B1 (fr) Formulations injectables de fosnetupitant physiologiquement equilibrees
MX2010008170A (es) Vacunas para influenza canina.
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
PH12018500372A1 (en) Fcv recombinant vaccines and uses thereof
FR3081870B1 (fr) Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie
ZA201706967B (en) Modification of african horse sickness virus vp7 protein